Adjuvant trastuzumab regimen for HER2-positive early-stage breast cancer: a systematic review and meta-analysis

Anne Julienne Genuino; Usa Chaikledkaew; Ong The Due; Thanyanan Reungwetwattana; Ammarin Thakkinstian

Expert Review of Clinical Pharmacology · 2019 · Tập 12(8) · 815-824

DOI Trang nguồn Toàn văn RIS BibTeX

Tóm tắt

Objective: Breast cancer remains to be the globally leading female cancer. About 15% to 20% of breast cancers have human epidermal growth factor receptor 2 (HER2)-positive tumors – a more aggressive breast cancer subtype with shortened survival. In the light of new and updated trial data on trastuzumab therapy for HER2-positive early-stage breast cancer (EBC), we conducted a systematic review and meta-analysis to update the pooling of its relative treatment effects.Methods: Systematic search was performed through Pubmed and Scopus to identify studies comparing survival outcomes and risks of heart toxicity effects of adjuvant trastuzumab with chemotherapy versus chemotherapy alone for HER2-positive EBC patients.Results: Based on the eight included studies in the review, combining trastuzumab with chemotherapy continues to show lowered death and relapse risks by one-third. The decision to initiate trastuzumab, however, needs to be prudently deliberated as two to three times more cardiotoxicity risk was shown to be associated with its use.Conclusion: Administering adjuvant trastuzumab in a weekly cycle concurrently with anthracycline-taxane chemotherapy regimen appears to be a preferable option to optimize its favorable effect in improving DFS and to prevent significantly higher risk for cardiotoxic effects.

Nguyên văn tóm tắt của bài gốc đăng trên Expert Review of Clinical Pharmacology.

Thông tin công bố

Thông tin thư mục do HERAC biên tập và đối chiếu với trang nguồn. Vui lòng đọc và trích dẫn tài liệu gốc.